AML blasts (n = 10) were treated with 50 nM of volasertib for 24 hrs and we identified five patients that showed upregulation of surface CD33 and five patients that showed minimal change in surface expression of CD33 following treatment. The gene discussed is CD33; the disease is acute myeloid leukemia.